Answers are grounded in this paper and cite their sources.
Small-cell lung cancer (SCLC) is an aggressive malignancy characterised by early metastatic dissemination, frequent relapse and poor long-term survival. Despite advances in immunotherapy, durable disease control remains challenging, highlighting the need to identify therapeutic vulnerabilities beyond conventional tumour-cell killing and immune checkpoint inhibition. Here, we uncover an unexpected contribution of Fas-Fas ligand (FasL) signalling to SCLC metastatic progression and demonstrate the therapeutic potential of targeting this pathway. Using an autochthonous Rb1/Trp53-deficient mouse model, we show that genetic Fas deletion markedly suppresses liver metastatic disease, identifying a previously unrecognised contribution of Fas signalling to metastatic progression. Notably, despite this antimetastatic effect, Fas deletion during tumour initiation did not improve survival and was accompanied by pronounced alterations in pulmonary tissue architecture. As these alterations may reflect adverse consequences of Fas deletion in non-malignant pulmonary populations, we reasoned that pharmacological FasL blockade in established disease could provide therapeutic benefit while circumventing the detrimental consequences for pulmonary tissue homeostasis associated with genetic Fas deletion. Remarkably, only six administrations of a soluble Fas-Fc fusion protein over three weeks significantly prolonged survival and substantially reduced the incidence and burden of liver metastases. FasL blockade was also associated with enhanced inflammatory and immune-response transcriptional signatures in the liver, while its combination with anti-PD-1 increased pulmonary immune-cell accumulation without conferring additional survival benefit. These data suggest that the biological consequences of targeting this pathway may depend on the timing and cellular context of intervention. Together, our findings identify Fas-FasL signalling as an unexpected regulator of SCLC metastatic progression and establish FasL blockade as a promising therapeutic strategy capable of prolonging survival in established disease beyond conventional immune checkpoint inhibition.
No takes yet. Share an insight, caveat, or question.
Saggau et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: